NEW INHIBITORS AGAINST accD3 GENE OF MYCOBACTERIUM TUBERCULOSIS, IN-SILICO STUDY AND IN -VITRO APPLICATIONAbstract
Mycobacterium tuberculosis (Mtb) is a pathogenic bacteria species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Tuberculosis (TB) is the leading cause of death in the world from a bacterial infectious disease. This antibiotic resistance strain lead to development of the new antibiotics or drug molecules which can kill or suppress the growth of Mycobacterium tuberculosis. The aim of this study is discovery a new drug molecules against the product of accD3 gene which play a vital role in mycolic acid biosynthesis pathway (MAP). As a first step accD3 gene amplified from the complete genome of Mycobacterium tuberculosis Iraqi isolates and sequenced, eight out of twenty of the resulted sequences were chosen to achieve the in silico studies, these sequences have deposited in GenBank database with strain names (ALQM1, ALQM2, ALQM3, ALQM4, ALQM5, ALQM6, ALQM7, ALQM8 ) and Accession numbers (LC006979, LC008196, LC009412, LC009414, LC034168, LC038020, LC041163, LC041368) respectively, two drug molecules resulted from in silico studies and used in the practical application to prove the in vitro inhibitory ability of these molecules on viable cells of M. tuberculosis, REMA which is a colorimetric assay was used in this research to estimate the inhibitory application of these molecules.